

**Manulife Investment Management I plc
(the Company)**

(the Company is an open-ended investment company with variable capital constituted as an umbrella fund with segregated liability between its sub funds under the laws of Ireland authorised and regulated by the Central Bank of Ireland pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 as may be amended, supplemented or consolidated form time to time) (the **UCITS Regulations**)

27 OCTOBER 2022

**ADDITIONAL INFORMATION FOR INVESTORS IN THE UNITED
KINGDOM**

Information contained herein is selective, containing specific information in relation to the Company. This document (the UK Country Supplement) forms part of and should be read in conjunction with the prospectus for the Company dated 1 April 2021 (and any Addenda or Supplements thereto) (together the “Prospectus”).

The Company has been granted temporary recognition under Part XVII of the Financial Services and Markets Act 2000 as amended (the “FSMA”), on the basis of the Temporary Marketing Permissions Regime contained in Regulation 62 of the Collective Investment Schemes (Amendment etc.) (EU Exit) Regulations 2019, for the following sub-funds:

1. Manulife Global Quality Growth (Ex U.S.) Fund
2. Manulife Strategic Income Opportunities Fund
3. Manulife U.S. Large Cap Equity Fund (the Sub Funds).

This document is for distribution in the United Kingdom only.

Words and expressions defined in the Prospectus shall, unless the context otherwise requires, have the same meaning when used herein.

If you are in any doubt about the contents of this document you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser.

This UK Country Supplement constitutes neither an offer by the Company or by any other person to enter into an investment agreement with the recipient of this document nor an invitation to the recipient to respond to the document by making an offer to the Company, or to any other person, to enter into an investment agreement. Investors who have any doubt about or wish to discuss the suitability of an investment in the shares and/or obtain further information on the shares should contact an independent financial advisor. Nothing in this document should be construed as investment advice.

IMPORTANT

The promotion of the Company and the Sub Funds and the distribution of the Prospectus in the United Kingdom are in accordance with this law.

Some or all of the rules made under the FSMA for the protection of retail clients will not apply to an investment in the Company and compensation under the Financial Services Compensation Scheme will generally not be available to investors in the United Kingdom.

An investor in the United Kingdom who enters into an investment agreement with the Company to acquire shares in response to the Prospectus will not have the right to cancel the agreement under the cancellation rules made by the Financial Conduct Authority in the United Kingdom (the **FCA**). The agreement will be binding upon acceptance of the order by the Company.

UNITED KINGDOM FACILITIES AGENT

The Manager of the Company, Manulife Investment Management (Ireland) Limited, has appointed Manulife Investment Management (Europe) Limited (the **Facilities Agent**) as its facilities agent. The facilities are located at the offices of the Facilities Agent, One London Wall, London EC2Y 5EA, United Kingdom.

DOCUMENTS AVAILABLE FOR INSPECTION

At these facilities any person may:

1. inspect (free of charge) a copy (in English) of:
 - (i) the Company's memorandum and articles of association;
 - (ii) any instrument amending the Company's memorandum and articles of association;
 - (iii) the latest version of the Prospectus and the supplements of the Company;
 - (iv) the latest version of the applicable key investor information documents (the **KIIDs**);
 - (v) the latest annual and half-yearly reports most recently prepared and published by the Company; and
 - (vi) any other documents specified in the Prospectus as being available for inspection.
2. obtain copies of the documents listed above free of charge;
3. obtain information (in English) about any Sub Fund and the most recently published prices relating to its shares;
4. make a complaint about the operation of the Company, which complaint the Facilities Agent will transmit to the Company; and
5. any shareholder may arrange for redemption of shares and arrange payment of redemption proceeds at the office of the Facilities Agent. Redemptions will be effected as set out under "How to Redeem Shares" in the Prospectus.

FEES AND EXPENSES

Information relating to the fees and expenses payable by investors in each of the Sub Funds is set out in the section of the Prospectus headed "Fees and Expenses". The attention of investors and/or prospective investors is drawn to the information relating to fees and expenses set out therein. Fees and expenses, including the Facilities Agent, will be charged at normal commercial rates.

TAXATION

Subject to their personal circumstances, shareholders resident in the United Kingdom, for United Kingdom tax purposes will be liable to United Kingdom income tax or corporation tax in respect of dividends or other distributions of an income nature made by the Sub Fund(s) in which they invest (including reportable income in respect of classes with reporting fund status or distributions that are automatically reinvested). Prospective investors should consult their own professional advisors on the implications of making an investment in, and holding or disposing of shares and the receipt of distributions with respect to such shares under the laws of the United Kingdom and any other countries in which they are liable to taxation.

Shareholders should note, the "Taxation" section in the Prospectus along with relevant sections of the Prospectus do not constitute legal or tax advice.